A modified version of Vitaxin, a humanized monoclonal IgG1 antibody to alpha(v)beta(3)integrin. Exhibiting improved affinity to alpha(v)beta(3)integrin compared to first-generation Vitaxin, Vitaxin-2 blocks the binding of ligands, such as vitronectin, to alpha(v)beta(3) integrin, thereby inhibiting endothelial cell-cell interactions, endothelial cell-matrix interactions, and angiogenesis. (NCI04) [ ]